Science and Research

eXALT3

Phase 3 Randomized Study Comparing Ensartinib to Crizotinib
in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung
Cancer (NSCLC) Patients

Study details
Study-ID: 2015-004147-40
Study-ID: 2015-004147-40
DZL Disease Area: LC
DZL Disease Area: LC
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL recruiting center
DZL Role: DZL recruiting center
Funding: Externally - industry
Funding: Externally - industry
DZL Participating Sites: BIH / Charité - Associated Partner
DZL Participating Sites: BIH / Charité - Associated Partner
Start Date: 01.02.2017
Completion Date: 22.05.2024
Status: Closed
Status: Closed
DZL recruiting center


close
chevron-down

Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.